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Abstract
Summary Alveolar bone mineral density (BMD) measured
by radiography standardized by aluminum step wedge
pasted on the film and digitized by a computer system
was significantly higher around osteonecrosis lesions than
in control cases in a pilot case–control study. High alveolar
bone density appears useful as a local risk factor for
bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Introduction In an attempt to find a reliable test method
predicting the occurrence of BRONJ in addition to various
risk factors suggested, an increase of alveolar bone density
near the necrotic lesions was found by computerized
radiogrammetry using dental films pasted with an alumi-
num step wedge (Bone RightⓇ, Dentalgraphic⋅Com
Company, Himeji) in six cases of BRONJ.
Methods The bone mineral density surrounding the osteo-
necrosis lesions showed distinctly higher density in BRONJ
cases compared with age-matched controls. In one subject
on bisphosphonate treatment in whom two extractions were
simultaneously carried out, BRONJ occurred only at the
location with extremely high alveolar bone density, but not
at the other site with normal density.
Conclusion This method may be useful in detecting a rise
of alveolar BMD frequently occurring near the necrotic
lesion in subjects with impending risk for BRONJ.
Keywords Alveolarbonedensity(al-BMD).
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Jawboneosteonecrosis
Introduction
Asanominous complicationofthe mosteffective andpopular
treatments of osteoporosis, bone metastasis, and bone tumors,
bisphosphonate-related osteonecrosis of the jaw (BRONJ)
emerged with the first report of 36 cases by Marx in 2003 [1].
BRONJ is typically manifested by spontaneous exposure of
the jaw bone with pain and swelling. The delay in the
healing of the alveolar bone after dental extraction or other
surgical procedure along with gingival swelling and pus
discharge characterizes its course. The American Association
of Oral and Maxillofacial Surgeons and the American
Society for Bone and Mineral Research defined BRONJ
with three characteristics: (1) use of bisphosphonate at
present or in the past, (2) exposure of the necrotic jaw bone
for 8 weeks or longer, and (3) absence of history of radiation
therapy on the jaw area [2, 3].
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DOI 10.1007/s00198-009-1021-zEpidemiological and clinical risk factors such as
intravenous injection of a large dose of bisphosphonate,
use of potent nitrogen-containing bisphosphonate at
higher doses and over longer period, presence of cancer,
diabetes mellitus, and other debilitating conditions, and
treatment with irradiation or corticosteroid were also
pointed out [4-6]. Surgical intervention including dental
extraction appears to represent an imminent, almost
prerequisite risk [7]. No effective tests predicting the
occurrence of BRONJ are yet available. Pronounced fall
of CTX, a marker of bone resorption, evidently a
bisphosphonate effect, was also reported to occur in some
patients with BRONJ [8].
In the process of searching for a readily available
screening method for the occurrence of BRONJ, a new
radiogrammetric method on the alveolar bone mineral
density was developed using aluminum step wedge, pasted
on dental film, to characterize alveolar bone under
imminent danger for BRONJ [9, 10].
Materials and methods
Selection of the test subjects
Subjects with pathologically established cases of BRONJ
after dental extraction were selected for alveolar bone
density measurement. All of them had been treated with
bisphosphonates and exposed to systemic risk factors for
BRONJ such as glucocorticoid treatment or infection.
Controls represented all subjects with age difference less
than ±2 years from among subjects under care by the
authors without history of bisphosphonate treatment,
irradiation, or dental surgical treatment, also subjected to
alveolar BMD (al-BMD) measurement by Bone Right
radiogrammetry.
Measurement of alveolar bone density
Dental X-ray films were taken and alveolar bone density at
the root of the first mandibular premolar measured, as
described elsewhere [9], using an originally designed image
editing software (No. PCT/jp2004/010815). A line was
drawn at the apex of the root, parallel to the boundary of
the cement–enamel junction. Another line was drawn
halfway between the cement–enamel junction and the apex
of the root. Lines were then drawn perpendicular to those
lines at the mesial and distal spaces of the first premolar.
The X-ray film density in the area of the resulting
rectangles was measured by first dividing the area into
pixels with sides 1/1,524 cm in length. The brightness in
each pixel was then compared with a scale consisting of
256 steps of brightness (Fig. 1).
In order to align and standardize the brightness and
contrast among the X-ray pictures for comparison of
the results of measurement among X-ray pictures taken
on different occasions, an X-ray picture taken for a
normal, healthy person (i.e., a 23-year-old woman
having 100% bone mineral density in the example being
described) was used as a reference. A histogram hist[x]
of a color bar on the reference picture was normalized
according to Eq. 1. Then, the normalized histogram
hist[x] is substituted in Eqs. 2 and 3 to thereby calculate
the brightness mean value, mean, and the standard
deviation, SD, which are referred to as the reference mean
value, RefMean, and the reference deviation, RefSD,
respectively.
Similarly, for each of the pictures to be corrected, the
histogram hist[x] of its color bar is normalized and the
brightness mean value and the SD for that picture
calculated. Mean, the mean value of the brightness thus
calculated, and SD, standard deviation, RefMean, the
reference mean value, and RefSD, the reference deviation,
are substituted in Eq. 4 to correct the respective pictures
Fig. 1 Geometry of alveolar
bone measurement. a Alumi-
num step wedge for calibration.
b Calibration of density between
standard aluminum wedge and
maximum/minimum density.
c Defining the area of interest
for the alveolar bone density
816 Osteoporos Int (2010) 21:815–825Table 1 Comparison of al-BMD between cases of BRONJ and age-matched controls (seven cases each)
Case no. Age Al-BMD Control no. Age Al-BMD Difference (Student's t test)
Case 1 75 184.1 Control 1-1 70 73.0 **
175.6 1-2 75 57.6 t=6.73
184.5 1-3 75 23.0 p=0.0001
(Mean 181.3) 1-4 75 108.5
1-5 75 85.0
1-6 76 53.0
1-7 76 33.8
Mean ± SD 74.6±1.9 61.9±29.5
Case 2 75 132.1 Control 2-1 70 73.0 **
123.6 2-2 75 57.6 t=5.42
120.4 2-3 75 23.0 p=0.0073
(Mean 125.3) 2-4 75 108.5
2-5 75 85.0
2-6 76 53.0
2-7 76 33.8
Mean ± SD 74.6±1.9 61.9±29.5
Case 3 61 150.2 Control 3-1 60 78.8 ns
98.5 3-2 60 81.2 t=1.86
84.7 3-3 60 95.1 p=0.0991
(Mean 111.1) 3-4 60 96.0
3-5 60 83.6
3-6 61 81.6
3-7 61 95.0
Mean ± SD 60±0 87.3±17.2
Case 4 49 190.0 Control 4-1 50 80.8 **
189.1 4-2 50 99.9 t=6.09
157.6 4-3 51 58.4 p=0.003
(Mean 178.9) 4-4 51 108.8
4-5 51 63.0
4-6 51 96.1
4-7 51 116.0
Mean ± SD 50.6±0.4 89.0±22.2
Case 5 47 138.6 Control 5-1 49 64.5 **
152.5 5-2 49 83.9 t=7.57
168.4 5-3 48 66.1 p=0.0001
(Mean 153.2) 5-4 48 91.2
5-5 46 63.5
5-6 45 93.2
Mean ± SD 47.1±1.8 77.0±13.9
Case 6 60 214.1 Control 6-1 60 78.8 **
229.4 6-2 60 81.2 t=18.81
200.5 6-3 60 95.1 p<0.0001
(Mean 214.7) 6-4 60 96.0
6-5 60 83.6
6-6 61 81.6
6-7 61 95.0
Mean ± SD 60.3±0.5 87.3±7.7
Total 61.2±12.1 160.8±39.4 61.3±10.8 77.7±22.6 **
t=7.10
p<0.0001
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corrected brightness value Y′(i,j) for each picture.
hist x ½ ¼
Num x ½ 
TotalNum
ð1Þ
where x (0≤x≤255) is gradation, Num[x] is the number of
pixels for the gradation x in the color bar, and TotalNum is
the total number of pixels of the color bar.
Mean ¼
X 255
x¼0
x   hist x ½  fg ð2Þ
SD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X 255
x¼0
x   Mean ðÞ
2   hist x ½ 
no
v u u t ð3Þ
Y' i;j ðÞ ¼
RefSD
SD
  Yi ;j ðÞ   Mean fg þ RefMean ð4Þ
where Y(i,j) is the brightness value of a picture before correc-
tion is provided and (i,j) is a coordinate of a given pixel.
Using a thin adhesive aluminum step wedge pasted on
the X-ray film, pictures of regions around the first right
mandibular premolar tooth were taken, with a special
caution to place the X-ray tube vertical to the film. The
dental X-ray film after exposure is then taken into a
laptop computer using a scanner. Data and histogram of
the al-BMD were recorded on the screen in a few minutes
using a software (Bone RightⓇ, Dentalgraphic⋅Com
Company) [9, 10]. This technique may also be applied
s i m i l a r l yt oa n yt o o t hi nap a n o r a m af i l mc o v e r i n gt h e
whole series of the teeth in an individual. As shown in
Table 1, al-BMD showed a significantly negative coeffi-
cient regression on age.
In summary, this new method of standardization of the
results of measurement of alveolar bone density made it
possible to compare the brightness data accurately between
films taken with time intervals. The use of aluminum step
wedge is not for direct comparison of brightness between
films but for normalization and standardization of the data by
computation; as the result, cv of 1.94% was achieved on
measurement of al-BMD in 20 subjects at 2-week intervals.
Case report and results of measurement
Case 1: BRONJ occurrence adjacent to high al-BMD region
but not adjacent to normal density on double extraction
The first case is a 75-year-old woman with multiple
myeloma treated with 10 mg monthly intravenous incadr-
onate for 5 years along with dexamethasone, ranimustine,
vincristine, and interferon. In June 2006, right maxillary
canine, right maxillary first premolar, and left mandibular
first molar were extracted.
As shown in Fig. 2a, a dental X-ray film view revealed
disappearance of the trabecular structure of the mandible.
Pathological findings were characteristic of BRONJ with
scarcely any osteocytes visible in the area involved; a radio-
opaque area surrounded by relatively radiolucent area
interspersed with bacterial flora and inflammatory granula-
tion tissue, indicating chronic suppurative osteomyelitis.
The bone mineral density was extremely high around the
BRONJ lesion, 181.3±5.0 (6, 7, 8, means ± SD, N=3), far
exceeding the mean bone mineral density in healthy young
subjects and significantly higher than the density around the
non-necrotic areas, 146.4±19.1 (1, 2, 3, mean ± SD, N=3)
where no BRONJ occurred (Fig. 2a). Although right
maxillary canine and first premolar as well as left
mandibular first molar were also extracted along with the
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Student's t test revealed significant difference between each pair of cases 1, 2, 4, 5, and 6 and controls, but not between case 3 and controls.
Overall statistical analysis showed a highly significant difference at p=0.0001
(**p<0.01)
Table 1 (continued)
818 Osteoporos Int (2010) 21:815–825left mandibular molar, BRONJ developed only around the
left first molar of the mandible. Since the al-BMD around
the right canine and first premolar of the maxilla was low
[30.6 and 42.7 (9, 10)], unusually high local al-BMD are
apparently associated with BRONJ. Detection and evalua-
tion of locally high BMD in the jaw bone apparently made
an early detection of BRONJ possible. Apparently, dental
extraction and accompanying tissue damage, infection,
hemorrhage, etc. accelerate or provoke infectious or necrotic
process in the development of BRONJ. Seven age-matched
control cases showed al-BMD of 61.9±29.5, significantly
lower than in this case (p<0.0001) as shown in Table 1.
   
 
 
      
   
 
Fig. 2 a Case 1, 75-year-old
female. Panorama X-ray film
and results of al-BMD measure-
ment. No osteonecrosis is noted
around the first premolar of the
right mandible [1-3], with high
al-BMD values 130–167. At
sites 9 and 10, on the contralat-
eral side with extraction, no
BRONJ occurred and al-BMD
stayed as low as 30–42. At site 5
exhibiting chronic suppurative
osteomyelitis alone, al-BMD
stayed within normal range,
120. At sites 6, 7, and 8 around
BRONJ which occurred after
extraction, extremely high al-
BMD of 175–184 was noted.
b Case2, 75-year-old female.
Osteonecrosis is noted around
the right mandibular molar and
premolar regions 5, 6, and
8 around the site of extraction
with higher al-BMD than
regions 1, 2, 3, and 7 elsewhere.
c Case 3, a 61-year-old female
exhibited an extremely high al-
BMD of 150 after intravenous
zoledronate at site 2 around the
BRONJ lesion which followed
an extraction, but normal densi-
ty of 84–98 around the neigh-
boring teeth
Osteoporos Int (2010) 21:815–825 819Case 2: BRONJ following oral alendronate treatment,
5 mg daily for 6 years, for osteoporosis after 1-year
corticosteroid treatment for rheumatic polymyalgia
in a 75-year-old female
On initial examination on January 11, 2008, compression of
right mandibular molar region elicited tenderness and pus
discharge.
Extraction in October was followed by poor recovery. In
January 2008, sequestrum was removed and BRONJ noted on
pathological examination. Significantly higher al-BMD was
also noted around the BRONJ lesion (132.1, 123.6, 120.4)
than other sites and in control cases (Table 1 and Fig. 2b).
Case 3: BRONJ following intravenous zoledronate
treatment of metastasizing breast cancer
BRONJ appeared in a 61-year-old female carrying breast
cancer with bone and liver metastases on dental extraction
on May 29, 2007 after intravenous zoledronate (4 mg/
month) over a period of 1 year and 4 months. On initial
examination on September 10, 2007, the site of extraction,
left upper first molar, was surrounded by a region with a
high bone density, 150.4 versus 84.7, and 98.5 brightness in
the corresponding part of the alveolar bone under the two
neighboring teeth (Fig. 2c). Washing of the oral cavity is
still continued at present. Higher al-BMD was noted than in
other sites and control cases (Table 1).
Case 4: BRONJ and chronic suppurative periodontitis
following intravenous pamidronate and zoledronate
treatment for 17 months
A 49-year-old female with breast cancer with multiple bone
metastases to the bone, treated with pamidronate from
March 2004 and 4 mg/month zoledronate from April 2006,
was first seen on September 20, 2007. BRONJ appeared on
August 8, 2007, manifested by spontaneous exposure of
natural bone on the lingual side of the second molar of
the left mandible. The bone density at the apical portion
of the site of necrosis (190.0, 189.1, and 157.6) [1-3] was
definitely higher than the corresponding site in adjacent
tooth without necrosis (154.5 and 130.3) [5, 6] (Fig. 3a).
These values were also significantly higher than these in
seven age-matched controls (Table 1). In November 2007,
recurrence of breast cancer and metastasis to the sternum
was noted.
Case 5: BRONJ following intravenous zoledronate
treatment of breast cancer
Case 5 is a 47-year-old female. Diagnosis of cancer of the
right breast was made in November 2002 and bone
metastases detected in April 2007. Zoledronate (4 mg/month)
was given until March 2009. Wounds at bridge site noted in
November 2008 over the first left mandibular molar tooth
extracted at 20 years of age failed to respond to washing and
local debridement. Osteomyelitis of the jaw related to
bisphosphonate treatment was diagnosed. Significantly
higher al-BMD (138.6, 152.5, and 168.4) was also noted
around the BRONJ lesion than other sites and in control
cases (Table 1 and Fig. 3b).
Case 6: BRONJ following intravenous zoledronate
treatment of metastasizing breast cancer
A 60-year-old female with left breast cancer was found
with multiple metastases to lymph nodes on February 6,
2008. Dexamethasone (ten times) and zoledronate (4 mg,
14 times) were given in February 2008 and March 2009.
Fig. 2 (continued)
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April 2009. Delayed healing bone exposure and pus dis-
charge led to diagnosis of BRONJ. Significantly higher
al-BMD (214.1, 229.4, and 200.5) was also noted around
the BRONJ lesion than other sites and in control cases
(Table 1 and Fig. 3c).
Reference case
A case of radiation-associated necrosis of the jaw
Around the site of necrosis, 16, 17, and 18 as well as other
sites, high al-BMD was found after radiation therapy;
jaw bone necrosis occurred, though no bisphosphonate was
given.
This study was approved by the Institutional Review
Board of Japanese Association for the Promotion of State of
Art in Medicine.
Discussion
Impressively high al-BMD around the BRONJ lesion is
summarized in Table 1. Highly statistically significant difference
was found in individual cases as well as the whole series. It was
especially noteworthy that BRONJ occurred only near the site
with high al-BMD despite two similar dental extractions.
 
 
 
 
Fig. 3 a Case 4, a 49-year-old
female manifested mainly by
chronic suppurative periodonti-
tis with BRONJ despite intrave-
nous pamidronate and
zoledronate and no tooth ex-
traction. At the apical portion of
the bone exposure site and
neighboring legions, extremely
high al-BMD of 157–190 was
noted as shown. b Case 5,
a 47-year-old female exhibited
an extremely high al-BMD after
intravenous zoledronate. At sites
3, 6, and 8 around BRONJ
lesion, extremely high al-BMD
of 168–138 was noted. c Case 6,
a 60-year-old female exhibited
an extremely high al-BMD after
intravenous zoledronate. At sites
2, 3, and 4 around BRONJ
lesion, extremely high al-BMD
of 214–200 was noted
Osteoporos Int (2010) 21:815–825 821The computerized alveolar bone densitometry using
dental X-ray film appears to be handy and useful to detect
rises of local alveolar bone density with reference to the
occurrence of BRONJ, as suggested by the six cases
presented. In addition to the increase of jaw bone cortical
thickness and suppression of bone turnover, local
increases of alveolar bone density appears to contribute
to BRONJ possibly through compromised circulation and
physicochemical overload. Fall of the level of bone
turnover may suppress defense reaction against external
stimuli. Restricted angiogenesis may also occur along
with osteosclerosis, leading to ischemia and poor nutri-
tional supply interfering with wound healing process. On
the other hand, the increase of density may suggest a
response to nearby necrotic process already started to be
aggravated, completing the necrosis in the response to the
invasive procedure.
Radiation therapy also increases al-BMD. A 54-year-old
male (reference case) underwent radiation therapy for
cancer of the tongue on March 2, 2004 and given 20
courses of irradiation over a period of 2 months. Surgery
for the cancer was performed in May 2005. Osteonecrosis
of the jaw appeared on extraction of first molar of the right
mandible on February 2007 at another dental clinic, with
persistent bone exposure. On May 18, 2007, alveolar bone
density was measured on dental and panorama X-ray film.
High bone density of 171 to 191 brightness was noted
throughout this period. Al-BMD at corresponding site in
this case was as high as in case 1, probably indicating a
local risk for osteonecrosis of the jaw regardless of the
cause (Fig. 4).
BRONJ is apparently a multi-factorial disease caused
by systemic and local factors. As is evident from the
discussion above, the present method using dental X-ray
 
 
 
 
 
 
Fig. 3 (continued)
822 Osteoporos Int (2010) 21:815–825film with aluminum step wedge pasted makes it possible
to measure alveolar bone mineral density at selected sites
of the alveolar bone quantitatively with a higher sensitiv-
ity and reproducibility, unlike observation of panoramic
X-ray film of the whole series of teeth only providing an
overview or general impression. Since jaw bone has a
high turnover, with a tendency of accumulation of micro-
damage and development of hard, brittle, and inactive
bone in response to bisphosphonate therapy, detection of
increased alveolar bone density may be especially useful
to detect appearance of bone quality, which may be one of
the factors causing BRONJ.
Pronounced fall of CTX, a bone resorption marker, to
less than 100 pg/ml was pointed out by Marx et al. [8]a sa
systemic risk factor for BRONJ. Bisphosphonates increase
BMD through inhibition of osteoclastic bone resorption
as indicated by a reduction of circulating bone resorption
marker such as CTX. It is thus understandable that the
larger the dose becomes, the more serum CTX falls. In
view of the association of very low serum CTX with
occurrence of BRONJ, excessive fall of serum CTX may
serve as one of the risk factors for BRONJ. Such
systemic marker of bisphosphonates, however, may not
directly express local bone changes directly influencing
the occurrence of BRONJ, taking into consideration
factors such as bone quality and circulation in response
to regional toxic effect of bisphosphonate. Measurement
of the local al-BMD may therefore be more valuable as a
predictor for BRONJ than systemic or circumstantial risk
factors.
 
 
 
 
 
Fig. 3 (continued)
Osteoporos Int (2010) 21:815–825 823The limitation of this case–control study consists in its
pilot nature. The number of cases is also small. A
prospective planned approach is desirable and a simple
increase of the number of cases would not add to the
reliability. This study, nevertheless, would suggest a useful-
ness of the new simple computerized alveolar bone density
measurement using dental X-ray film. Attempts are also in
progress to improve accuracy of the data by introducing
thickness factor to simulate true three-dimensional density
instead of the current two-dimensional projective density on
the X-ray film. Prospective and systematic evaluation of al-
BMD with reference to the occurrence of BRONJ is in order
to test the significance of high al-BMD as a local risk factor
for BRONJ.
Fig. 4 Reference case, a 54-
year-old male with osteonecro-
sis of the jaw following radia-
tion and tooth extraction
exhibited high al-BMD values
of 159–207 including the site
around extraction and develop-
ment of osteonecrosis of the jaw
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